CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Najat Khan

Chief Executive Officer and President, Recursion Pharmaceuticals

Search every verified Najat Khan interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. On September 24, 2026, Najat Khan hosted the sixth episode of TechBio Talks, featuring Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital. During the conversation, Khan and Cheatham discussed the convergence of artificial intelligence and clinical data in transforming the measurement of human physiology and disease. Khan highlighted the role of AI as a measurement tool, citing examples such as using electrocardiograms to detect structural heart disease and cardiac amyloidosis, and emphasized the importance of first-principles understanding in biomedical innovation. In the episode, Khan also addressed the current financing environment for biotech platforms, noting that private markets often capitalize on the possibility that a platform might produce many drugs, while today's focus is on evidence that a platform can produce one. She expressed a view that AI's impact on measuring physiology and disease could surpass its role in back-office automation across the healthcare and life sciences industries, which she described as a multi-trillion-dollar sector.

Recent appearances

  • TechBio Talks Episode 6: Breyer Capital's Morgan Cheatham with Host Najat Khan

    September 24, 2026 · 📺 Recursion

    In this episode of TechBio Talks, host Najat Khan, PhD, CEO and President of Recursion, talks to Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital, about how artificial intelligence and clinical data are converging to transform the measurement of human physiology and disease. Morgan is a physician, medical geneticist, and investor who has spent nearly a decade backing category-defining companies spanning diagnostics, therapeutics, and care delivery. They discuss how AI is reshaping the fundamentals of biotech value creation, the vital concept of "modalit…

    Watch on YouTube ↗

  • Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers

    March 19, 2026 · 📺 BioCentury Video

    As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration. View full story: https://www.biocentury.com/article/65... #ArtificialIntelligence #DrugDevelopment #AgenticAI #ClinicalProof #BiopharmaInnovation 00:00 - Introdu…

    Watch on YouTube ↗

  • TechBio Talks: Katie Couric and Najat Khan

    February 11, 2026 · 📺 Recursion

    Recursion CEO and President Najat Khan talks to award-winning journalist, filmmaker, podcaster, and co-founder of Stand Up to Cancer, Katie Couric about their personal motivations; the current state of AI drug discovery; and exciting proof points like Recursion’s potential first-in-disease treatment for the rare disease familial adenomatous polyposis (FAP).

    Watch on YouTube ↗

  • TechBio Talks Episode 1: MIT's Regina Barzilay with Host Najat Khan

    September 03, 2025 · 📺 Recursion

    In the first episode of TechBio Talks, host Najat Khan talks to Regina Barzilay -- Distinguished Professor at Massachusetts Institute of Technology and AI faculty lead at MIT Jameel Clinic, MacArthur “Genius Grant” recipient and member of the National Academies of Medicine and Engineering. Regina and Najat discuss everything from Regina’s work on early cancer detection models to what sparked the collaboration behind Boltz-2, the first open-source AI model for highly accurate protein binding affinity predictions from MIT alongside Recursion – and how it’s already leading to new discoveries.…

    Watch on YouTube ↗

  • Ep174: Najat Khan on the TechBio Movement

    June 11, 2025 · 📺 The Long Run with Luke Timmerman

    Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

    Watch on YouTube ↗

  • Najat Khan, PhD at Recursion's JPM Event: The Convergence of Biology, ML & Supercomputing Is Here

    February 11, 2025 · 📺 Recursion

    In her welcome remarks at Recursion's "Era of TechBio" event at the 2025 J.P. Morgan Healthcare Conference, Recursion Chief R&D and Chief Commercial Officer Najat Khan, PhD shares why she is excited by the progress over the past year -- including 10 pipeline programs, 10 advanced discovery programs, and 10 active partnered programs.

    Watch on YouTube ↗

  • How We're Leveraging AI to Address Key Pain Points in Drug Discovery -- Najat Khan, PhD on Bloomberg

    January 23, 2025 · 📺 Recursion

    Speaking to Bloomberg Radio, Chief R&D and Chief Commercial Officer Najat Khan, PhD shared how Recursion is directly addressing the pain points that lead to failures in the clinic through AI-enabled Maps of Biology. On Recursion’s AI-enabled approach. “What Recursion is doing is leveraging AI and high-quality data that is generated in our own labs at scale” to build AI algorithms that are used to “really understand what is driving the disease.” Then, “we use generative AI to design molecules that someone –even a PhD organic chemist – never considered before.” On using AI to improve the s…

    Watch on YouTube ↗

  • Fireside chat featuring Najat Khan and Jacqueline Barendregt

    January 02, 2025 · 📺 IDEA Pharma

    Fireside Chat: Najat Khan & Jacqueline Barendregt | Recursion's Vision for AI in Biotech Join Najat Khan, Chief AI Officer and Chief Commercial Officer at Recursion, and Jacqueline Barendregt as they dive into the transformative role of AI in drug discovery and development. This engaging discussion covers: 🌟 Najat Khan’s Career Journey From leading R&D strategy and data science at Johnson & Johnson to driving innovation at Recursion, Najat shares insights on integrating AI and science for patient-focused solutions. 💊 Tackling Unmet Medical Needs Discover how Recursion is addressing the 80%…

    Watch on YouTube ↗

  • Najat Khan, PhD Gives Afternoon Convocation at Download Day

    June 28, 2024 · 📺 Recursion

    Recursion's Chief R&D Officer and Chief Commercial Officer, Najat Khan, PhD presents at Download Day 2024. About Recursion: Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships a…

    Watch on YouTube ↗

Other executives at Recursion Pharmaceuticals

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →